scholarly journals Scrambler Therapy for the Treatment of Pain in Schwannomatosis

2022 ◽  
Author(s):  
Thomas J Smith ◽  
Michael Erdek ◽  
Tyler Murphy
Keyword(s):  
Neuropathic Pain ◽  
Normal Function ◽  
Complete Relief ◽  
Scrambler Therapy

Abstract Purpose: Schwannomatosis patients (SP) suffer from chronic nerve pain that is often inadequately relieved. Scrambler Therapy (ST) can relieve neuropathic pain quickly, safely, and inexpensively. We successfully treated a patient with Scrambler Therapy, adding another tool to the methods used to treat SP pain.Methods: We treated her with 5 daily sessions of ST, each for 40 minutes.Results: Complete relief of pain and hyperalgesia, with return to normal function, by day 5, that has persisted.Conclusion: Scrambler Therapy may be an effective way to treat schwannomatosis pain, and deserves further research.

scholarly journals Differential response to scrambler therapy by neuropathic pain phenotypes

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Young Gi Min ◽  
Hyun Seok Baek ◽  
Kyoung-Min Lee ◽  
Yoon-Ho Hong
Keyword(s):  
Neuropathic Pain ◽  
Treatment Outcome ◽  
Rating Scale ◽  
Numerical Rating Scale ◽  
Brief Pain Inventory ◽  
Differential Response ◽  
Open Label ◽  
Numerical Rating ◽  
Scrambler Therapy ◽  
Post Hoc

AbstractScrambler therapy is a noninvasive electroanalgesia technique designed to remodulate the pain system. Despite growing evidence of its efficacy in patients with neuropathic pain, little is known about the clinical factors associated with treatment outcome. We conducted a prospective, open-label, single-arm trial to assess the efficacy and safety of scrambler therapy in patients with chronic neuropathic pain of various etiologies. A post-hoc analysis was performed to investigate whether cluster analysis of the Neuropathic Pain Symptom Inventory (NPSI) profiles could identify a subgroup of patients regarding neuropathic pain phenotype and treatment outcome. Scrambler therapy resulted in a significant decrease in the pain numerical rating scale (NRS) score over 2 weeks of treatment (least squares mean of percentage change from baseline, − 15%; 95% CI − 28% to − 2.4%; p < 0.001). The mean score of Brief Pain Inventory (BPI) interference subdimension was also significantly improved (p = 0.022), while the BPI pain composite score was not. Hierarchical clustering based on the NPSI profiles partitioned the patients into 3 clusters with distinct neuropathic pain phenotypes. Linear mixed-effects model analyses revealed differential response to scrambler therapy across clusters (p = 0.003, pain NRS; p = 0.072, BPI interference subdimension). Treatment response to scrambler therapy appears different depending on the neuropathic pain phenotypes, with more favorable outcomes in patients with preferentially paroxysmal pain rather than persistent pain. Further studies are warranted to confirm that capturing neuropathic pain phenotypes can optimize the use of scrambler therapy.

Scrambler therapy for noncancer neuropathic pain

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Salahadin Abdi ◽  
Matthew Chung ◽  
Giuseppe Marineo
Keyword(s):  
Neuropathic Pain ◽  
Scrambler Therapy

Treatment of central and spinal cord neuropathic pain with Scrambler Therapy.

2019 ◽  
Vol 37 (31_suppl) ◽  
pp. 127-127
Author(s):  
Thomas J. Smith ◽  
David Kamson ◽  
Maureen A Mealy ◽  
Steve D'Amato
Keyword(s):  
Spinal Cord ◽  
Radiation Treatment ◽  
Transverse Myelitis ◽  
Pain Syndrome ◽  
Normal Function ◽  
Electrode Placement ◽  
Central Pain ◽  
Patient Pain ◽  
Scrambler Therapy ◽  
Thalamic Pain Syndrome

127 Background: Central pain caused by spinal cord or brain injury tends to be severe and refractory despite aggressive treatment, such as in thalamic pain syndrome, neuromyelitis optica spectrum disorder (NMOSD) and other forms of transverse myelitis, and spinal cord gliomas. Methods: We reviewed our experience with treatment of these relatively rare maladies with Scrambler Therapy, a noninvasive form of neuromodulation. Results: One transverse myelitis patient got substantial relief lasting months (Mealy M, Int J MS Care. 201), leading to the NMOSD trial. In a small, sham-controlled randomized trial, NMOSD patient pain scores were reduced in the ST arm from 5 to 1.5 at 30 days, P< 0.01, while the sham treatment gave no relief. (Neurology, resubmitted) Of three patients with pain due to thalamic strokes, surgery and/or radiation, treatment gave over 50% relief long-term in 2 of 3 (D’Amato S, A A Pract. 2018). In the one spinal cord glioma patient, pain in her index finger was reduced from 8-10/10 to 1-2/10 and treatment is ongoing. All successfully treated patients reported marked relief of allodynia and hyperalgesia, in addition to pain relief as reported previously (Marineo G, JPSM 2012). Conclusions: Scrambler therapy is a promising treatment modality for patients with these individually rare but collectively common forms of central pain. It has allowed return to more normal function in most patients, with reductions in pain medication use. Pictures of electrode placement and treatment plans will be shown, allowing others to do this safe and often effective treatment. Clinical trial information: NCT03452176.

α1-Adrenoceptors in Normal and Hyperalgesic Human Skin

1996 ◽  
Vol 91 (1) ◽  
pp. 73-77 ◽  
Author(s):  
Peter D. Drummond ◽  
Shiarne Skipworth ◽  
Philip M. Finch
Keyword(s):  
Neuropathic Pain ◽  
Reflex Sympathetic Dystrophy ◽  
Normal Skin ◽  
Cell Types ◽  
Normal Function ◽  
Chronic Neuropathic Pain ◽  
Sensory Abnormalities ◽  
Normal Individuals ◽  
The Mean ◽  
Dermal Papillae

1. Evidence of an adrenergic component of cutaneous hyperalgesia has recently been obtained in animal models of painful peripheral neuropathy. These findings have prompted speculation that an increased density or sensitivity of peripheral α-adrenoceptors contributes to sensory abnormalities and chronic neuropathic pain in conditions such as reflex sympathetic dystrophy. However, it is not known whether α-adrenoceptors are present at the site of nociception, either in hyperalgesic or normal skin. 2. We used the selective radioligand 125I-hydroxyphenyl-ethyl-aminomethyl-tetralone (HEAT) to label α1-adrenoceptors, and quantitative autoradiography to assess the relative density of these receptors in skin samples from seven normal individuals and from the hyperalgesic and pain-free limbs of five patients with reflex sympathetic dystrophy. The distribution of autoradiographic grains over the epidermis and dermis was investigated in 10 μm serial transverse sections. 3. α1-Adrenoceptors were identified in the epidermis and dermal papillae of normal individuals, and in the hyperalgesic and pain-free skin of patients with reflex sympathetic dystrophy. The density of α1-adrenoceptors was greater in the epidermis and dermal papillae than further down in the dermis. 4. The mean density of α1-adrenoceptors was significantly greater in the hyperalgesic skin of patients than in the skin of normal individuals (35.4 grains/1000 μm2 compared with 15.5 grains/1000 μm2, P > 0.01). The mean density of α1-adrenoceptors in the pain-free skin of patients (26.9 grains/1000 μm2) fell midway between receptor density in hyperalgesic skin and in the skin of normal individuals, and did not differ significantly from either. 5. Our findings indicate that α1-adrenoceptors are present in the epidermis, and suggest that their numbers may be increased in the hyperalgesic skin of patients with reflex sympathetic dystrophy. Further studies need to identify the dermal and epidermal cell types that express high densities of α1-adrenoceptors, and to investigate their normal function and role in neuropathic pain.

scholarly journals Differential Response to Scrambler Therapy by Neuropathic Pain Phenotypes

2021 ◽  
Author(s):  
Young Gi Min ◽  
Hyun Seok Baek ◽  
Kyoung-Min Lee ◽  
Yoon-Ho Hong
Keyword(s):  
Neuropathic Pain ◽  
Treatment Outcome ◽  
Rating Scale ◽  
Numerical Rating Scale ◽  
Brief Pain Inventory ◽  
Differential Response ◽  
Sensory Profile ◽  
Open Label ◽  
Numerical Rating ◽  
Scrambler Therapy

Abstract Scrambler therapy is a novel noninvasive electroanalgesia technique designed to remodulate the pain system. Despite growing evidence of its efficacy in patients with neuropathic pain, little is known about the clinical factors associated with treatment outcome. We conducted a prospective, open-label, single-arm trial to assess the efficacy and safety of scrambler therapy in patients with chronic neuropathic pain of various etiologies. A post-hoc analysis was performed to investigate whether cluster analysis of the Neuropathic Pain Symptom Inventory profiles could identify a subgroup of patients regarding neuropathic pain phenotype and treatment outcome. Scrambler therapy resulted in a significant decrease in the pain numerical rating scale (NRS) score over 2 weeks of treatment (least squares mean of percentage change from baseline, −15%; 95% CI, −28% to −2.4%; p < 0.001). The mean score of Brief Pain Inventory (BPI) interference subdimension was also significantly improved (p = 0.022), while the BPI pain composite score was not. Hierarchical clustering partitioned the patients into 3 clusters with distinct neuropathic pain phenotypes. Linear mixed-effects model analyses revealed differential response to scrambler therapy across clusters (p = 0.003, pain NRS; p = 0.072, BPI interference subdimension). Treatment response to scrambler therapy appears different depending on the pain-related sensory profile, with more favorable outcomes in patients with preferentially paroxysmal pain rather than persistent pain. Further studies are warranted to confirm that capturing neuropathic pain phenotypes can optimize the use of scrambler therapy.

A Review of Scrambler Therapy for Chronic Neuropathic Pain

2016 ◽  
Vol 5 (5) ◽  
Author(s):  
Alexandra M Lesenskyj ◽  
Christina R Maxwell ◽  
Shannon Brown ◽  
Ricardo A Cruciani
Keyword(s):  
Neuropathic Pain ◽  
Chronic Neuropathic Pain ◽  
Scrambler Therapy

Treatment of post-herpetic pain with scrambler therapy, a patient-specific neuro-cutaneous electrical stimulation device.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e19564-e19564
Author(s):  
Thomas J. Smith ◽  
Giuseppe Marineo
Keyword(s):  
Neuropathic Pain ◽  
Hematologic Malignancy ◽  
Primary Diagnosis ◽  
Patient Specific ◽  
Treatment Results ◽  
Before And After ◽  
Maximum Pain ◽  
Average Pain ◽  
Average Pain Score ◽  
Scrambler Therapy

e19564^ Background: Post herpetic neuropathy (PHN) is common in cancer and hematologic malignancy patients. It can be debilitating and difficulty to treat effectively. Scrambler therapy, a patient-specific neurocutaneous stimulation device, can be effective in treating chemotherapy induced neuropathy (JPSM 2010) and other neuropathic pain (JPSM 2012). Methods: We treated ten patients, 2 with cancer as their primary diagnosis, with refractory PHN Scrambler therapy at two institutions. Scrambler therapy was given as 30 minute sessions daily for 10 days. Pain was recorded before and after treatment. Results: The patient mean age was 54 ± SD 13 years, 6 men and 4 women, with a mean duration of PHN for 15.6 months (range 2.5 to 48 months) without satisfactory relief despite conventional drugs. The average pain score rapidly diminished from 7.64 ± 1.46 at baseline to 0.42 ± 0.89 at one month, a 95% reduction, with continued relief at 2 and 3 months. Patients achieved maximum pain relief with less than 5 treatments. Conclusions: Scrambler therapy appears to have a promising effect on PHN, with prompt and continued relief and no side effects. Further research is warranted. [Table: see text]

Scrambler therapy efficacy and safety for neuropathic pain correlated with chemotherapy-induced peripheral neuropathy in adolescents: A preliminary study

2018 ◽  
Vol 65 (7) ◽  
pp. e27064 ◽  
Author(s):  
Caterina Tomasello ◽  
Rita Maria Pinto ◽  
Chiara Mennini ◽  
Elena Conicella ◽  
Francesca Stoppa ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Peripheral Neuropathy ◽  
Efficacy And Safety ◽  
Therapy Efficacy ◽  
Scrambler Therapy ◽  
Preliminary Study
Sign in / Sign up

Export Citation Format

Share Document